AsclepiX Therapeutics, Inc.
Funding rounds
3 counted as startup funding. Open the number of investors for the round's details.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
AsclepiX Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Apr 2024).
SEC Form D · Apr 2024
The industry group it chose in its notices: Biotechnology.
SEC Form D · Apr 2024
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
No investor of AsclepiX Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Aleksander Popel | Executive officer | Apr 2024 |
| Amir Shojaei | Executive officer | Apr 2024 |
| Jill Tierney | Executive officer | Apr 2024 |
| Niranjan Pandey | Executive officer | Apr 2024 |
| Robert Dempsey | Executive officer | Apr 2024 |
| Kevin S. Slawin, MD | Executive officer | Jun 2020 |
| Wendy Perrow | Executive officer | Jun 2019 |
| Ben Askew | Director | Apr 2024 |
| Chris Garabedian | Director | Apr 2024 |
| Jordan Green | Director | Apr 2024 |
| Josh Barer | Director | Apr 2024 |
| Sapna Srivastava | Director | Apr 2024 |
| Steven Altschuler | Director | Apr 2024 |
| Aleksander S. Popel, PhD | Director | Jun 2020 |
| Jordan J. Green | Director | Jun 2020 |
| Joshua S. Barer | Director | Jun 2020 |
| Kevin S. Slawin, MD | Director | Jun 2020 |
| Sapna S. Srivastava | Director | Jun 2020 |
| Steven S. Altschuler, MD | Director | Jun 2020 |
| Wendy Perrow | Director | Jun 2019 |
| Aleksander Popel, PhD | Director | Oct 2018 |
| Joshua Barer | Director | Oct 2018 |
| Kevin Slawin, MD | Director | Oct 2018 |